Vyome operates a three‑pillar healthcare platform that combines biotech drug development, medical‑device acquisition, and AI‑driven data analytics to create therapies for underserved immuno‑inflammatory conditions. It advances clinical‑stage treatments such as VT1953 for malignant fungating wounds, an IMPDH‑targeting candidate for steroid‑intolerant uveitis, and VB1953 for antibiotic‑resistant acne, while leveraging cross‑border US‑India R&D and AI insights to accelerate development and improve patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with immuno‑inflammatory conditions such as malignant fungating wounds, uveitis, and antibiotic‑resistant acne have few or no effective therapies, leading to persistent pain, disfigurement, and reduced quality of life. The market for these underserved diseases is large and growing, yet development pipelines are limited.
Solution
Vyome builds a three‑pillar healthcare platform that integrates biotech drug development, medical‑device acquisition, and AI‑driven data analytics to address unmet needs in immuno‑inflammatory diseases. In biotech, it advances clinical‑stage therapies with novel mechanisms, such as VT1953 for malignant fungating wounds, an IMPDH‑targeting agent for steroid‑intolerant uveitis, and VB1953 for antibiotic‑resistant acne. The medical‑device pillar focuses on scaling proven technologies across markets, while the AI pillar leverages patient and clinical data to optimize outcomes and accelerate development. By operating across the US‑India innovation corridor, Vyome aims to deliver cost‑efficient, high‑impact treatments for rare and resistant conditions.
Target Audience
Primary customers are pharmaceutical partners, specialty clinicians, and healthcare systems seeking novel therapies for rare, refractory immuno‑inflammatory conditions, as well as investors focused on high‑growth biotech and med‑tech opportunities.
Features
- VT1953: first targeted therapy for malignant fungating wounds, achieving ~75% reduction in malodor with dual anti‑odor and anti‑inflammatory action; orphan drug designation potential.
- IMPDH‑based uveitis candidate: steroid‑sparing approach for patients unable to use corticosteroids, designed for a streamlined regulatory pathway in a rare indication.
- VB1953: next‑generation acne treatment combining DNA gyrase inhibition and TLR‑MD2 blockade, effective in clindamycin‑non‑responders and demonstrated safety in >550 patients, including a large Phase 2 trial.
- Integrated AI platform that aggregates clinical and real‑world data to inform trial design, patient selection, and post‑market outcome monitoring.
- Capability to acquire and scale existing medical‑device innovations, extending the therapeutic ecosystem beyond pharmaceuticals.
- Cross‑border R&D model leveraging scientific talent and capital efficiency across the United States and India.